Fate Therapeutics Inc $ 89.72 3.45 (4%)
Volume:
1,104,475
Avg Vol (1m):
1,041,408
Market Cap $:
8.41 Bil
Enterprise Value $:
8.01 Bil
PE Ratio:
0.00
PB Ratio:
20.39
Financial Strength | 5/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 4.96 | ||
| Equity-to-Asset | 0.62 | ||
| Debt-to-Equity | 0.25 | ||
| Debt-to-EBITDA | -0.57 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | 22.99 | ||
| Beneish M-Score | 2.66 | ||
| WACC vs ROIC | |||
Profitability Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -407.47 | ||
| Net Margin % | -551.59 | ||
| ROE % | -49.63 | ||
| ROA % | -34.31 | ||
| ROC (Joel Greenblatt) % | -246.03 | ||
| 3-Year Revenue Growth Rate | 4.1 | ||
| 3-Year EBITDA Growth Rate | -12.3 | ||
| 3-Year EPS without NRI Growth Rate | -11.1 |
FATE
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 20.39 | ||
| PS Ratio | 241.84 | ||
| EV-to-EBIT | -45.95 | ||
| EV-to-EBITDA | -46.55 | ||
| EV-to-Revenue | 254.85 | ||
| Current Ratio | 5.78 | ||
| Quick Ratio | 5.78 | ||
| Days Sales Outstanding | 64.04 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -22.3 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 20.39 | ||
| Earnings Yield (Greenblatt) % | -2.17 |